

Alberta Drug Benefit List (ADBL) Interim Update now available online

Please be advised that the **October 1, 2024** updates to the *Alberta Drug Benefit List (ADBL)* are posted online at ab.bluecross.ca/dbl/publications.php.

You can refer to the **October 1, 2024** updates for complete listings of products available by special authorization, drug products with changes to criteria for coverage, added products, new established interchangeable groupings, least cost alternative price changes, products with a price change, discontinued products and delisted products.

Note that the online *interactive Drug Benefit List (iDBL)* at ab.bluecross.ca/dbl/idbl_main1.php is a near real-time application and contains the most up-to-date information.

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross® has confirmed that the shortage for pms-Methylphenidate CR 20 mg Extended-Release Capsule (DIN 02536978) is resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the Least Cost Alternative (LCA) price policy will be reapplied to the following grouping effective **October 21, 2024**. The following grouping was removed from the Critical Supply Product List **September 20, 2024**:

METHYLPHENIDATE HCL

20 MG CONTROLLED-RELEASE CAPSULE

00002536978	PMS-METHYLPHENIDATE CR	PMS	\$ 0.9477
00002277158	BIPHENTIN	ELV	\$ 1.5300

Alberta Blue Cross has confirmed that the shortage for pms-Methylphenidate CR 50 mg Extended-Release Capsule (DIN 02537001) is resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 21, 2024**. The following grouping was removed from the Critical Supply Product List **September 20, 2024**:

METHYLPHENIDATE HCL

50 MG CONTROLLED-RELEASE CAPSULE

00002537001	PMS-METHYLPHENIDATE CR	PMS	\$ 2.0130
00002277190	BIPHENTIN	ELV	\$ 3.2445

continued next page

PHARMACY BENEFACT

continued from previous page

Alberta Blue Cross has confirmed that the shortage for Caspofungin 50 mg Injection (DIN 02460947), manufactured by Juno Pharmaceuticals Corp., is resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 28, 2024**. The following grouping was removed from the Critical Supply Product List **September 26, 2024**:

CASPOFUNGIN

50 MG / VIAL INJECTION

00002460947	CASPOFUNGIN	JUN	\$ 188.7000
00002244265	CANCIDAS	MFC	\$ 222.0000

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

